Ibogaine and Buspirone

Moderate caution. 5-HT1A partial agonist. Its serotonergic contribution is materially smaller than an SSRI's, but noribogaine is a potent serotonin reuptake inhibitor and the effects are additive, so it belongs in the serotonergic tally rather than outside it. CYP3A4 substrate. Flag to the medical team so it is counted alongside every other serotonergic agent when the total load is assessed. Timing of any taper is a physician decision and should not be inferred from the SSRI protocol.

Continue as prescribed — cleared by a measured lab value, not a waiting period. This medication is not stopped for treatment, and should not be stopped on our initiative — the condition it treats usually outranks the interaction. What it changes is monitoring: serum potassium and magnesium are measured before the flood dose and corrected to target, and the dose is deferred until those numbers are right rather than until a number of days have passed. Any change to the prescription belongs to the prescribing physician.

Serotonergic activity (serotonin syndrome). Noribogaine is a potent serotonin reuptake inhibitor. Combining it with another drug that raises synaptic serotonin (SSRIs, SNRIs, MAOIs, triptans, tramadol, MDMA, St John's Wort) can trigger serotonin syndrome — autonomic instability, hyperthermia, neuromuscular hyperactivity, and altered mental state. This is a leading cause of preventable harm in psychedelic medicine and the reason serotonergic medications carry the longest washout windows.

In many cases yes. Our medical team works with your prescribing physician to taper or substitute medications safely before treatment. The right substitution depends on the underlying condition you are treating with Buspirone — contact us for an individual review.